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Objective and background: The study aim is to provide long-term clinical outcome
after percutaneous coronary intervention (PCI) for unprotected left main coronary
arteries (ULMCA) stenosis with the first-generation (1st-gen) drug-eluting stents
(DES) in comparison to 2nd-gen DES, since this is largely unknown.
Methods: Between May 2002, and December 2014, a consecutive series of 656 all-
comer patients underwent a PCI for ULMCA stenosis at the Erasmus Medical Center.
A total of 235 patients were treated with 1st-gen DES, while a total of 421 patients
were treated with 2nd-gen DES.
Results: Overall, the population consisted of 73% males and 58% presented with an
acute coronary syndrome. Median follow-up time was 1,361 days (range from 0 to
5,031). At 5 years, the cumulative incidence of major adverse clinical events (the pri-
mary composite endpoint of all-cause death, any myocardial infarction or target lesion
revascularization; MACE) did not differ between 1st- and 2nd-gen DES (36.8 vs. 38.6%,
respectively, Log Rank p = .79, adjusted hazard ratio [HR] = 1.28 [95% confidence inter-
val (CI) 0.94–1.74]). No difference was found in the individual endpoints of all-cause
mortality (29.5 vs. 29% respectively, p = .88, adjusted HR = 1.19 [95% CI, 0.84–1.68]),
target vessel myocardial infarction (5.0 vs. 8.4%, p = 0.17, adjusted HR = 1.75 [95% CI,
0.78–3.96]) and target lesion revascularization (8.1 vs. 9.8%, p = .94, adjusted HR = 1.16
[95% CI, 0.59–2.29]) between the 1st- and 2nd-gen DES cohorts, respectively.
Conclusions: In this large cohort of consecutive patients treated for ULMCA stenosis,
no significant differences were found in the safety and efficacy of 1st versus 2nd-gen
DES at 5 years follow-up.
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1 | INTRODUCTION
Treatment of unprotected left main coronary artery (ULMCA) stenosis
by percutaneous coronary intervention (PCI) is now recognized as an
alternative to coronary artery bypass grafting (CABG) in selected
patients.1–4 A recent large-scale patient level meta-analysis demon-
strated no difference in long-term mortality in patients with left main
coronary artery disease treated with CABG or PCI (irrespective of SYN-
TAX score or diabetes).4 However, the vast majority of patients enrolled
in these trials were treated with either bare metal stents or first genera-
tion (1st-gen) drug eluting stents (DES).4 In order to decrease the inci-
dence of adverse events like late and very late stent thrombosis, 2nd
generation DES were developed with better deliverable alloys, less
thrombogenic surface and thinner struts.5–7 Although the success of
these device iterations was proven by better outcomes in a general PCI
population, little data are available on the potential benefit of the 2nd-
gen DES as compared to 1st-gen DES in real world patients with ULMCA
disease.8 Previous studies either primarily focused on 1st-gen DES, lacked
long-term follow-up or enrolled only selected patients.9–16 Therefore,
the aim of this study was to assess the 5-year clinical outcome of 1st-gen
versus 2nd-gen DES for the treatment of ULMCA stenosis.
2 | METHODS
2.1 | Patient selection and procedural characteristics
Between May 2002, and December 2014, all patients who underwent
PCI for ULMCA stenosis at our institution (Erasmus Medical Center, Rot-
terdam, the Netherlands) with either a 1st- or 2nd-gen DES were
included. ULMCA stenosis was defined as stenosis in either the ostial,
mid, distal segment and/or the bifurcation. While patients with failed
grafts on either the left anterior descending artery (LAD) or left circum-
flex artery (LCX) were included, patients with functioning LAD or LCX
grafts were excluded. Multiple segments could be stenosed at the same
time. In addition, the Medina classification was used to further identify
the specific characteristics of ULMCA bifurcation lesions.17 Main branch
stenting was defined as a stenting technique which did not involve a
stent implantation of either the proximal LAD or proximal LCX. Angio-
graphic success was defined as TIMI III flow in the left coronary system
and no residual relevant stenosis in the stented segment. 1st-gen DES
comprised sirolimus-eluting Cypher™ stents (Cordis Corporation, John-
son & Johnson, Warren, New Jersey) or paclitaxel eluting TAXUS™
stents (Boston Scientific Nattick, Massachusets). 2nd-gen DES included
everolimus-eluting Xience™ stents, Xience V™, Xience Prime™, Xience
Xpededition™ (Abbott Vascular, Santa Clara, California), Promus™ and
Promus Premier™ (Boston Scientific, Nattick, Massachusets), Biolimus
eluting BioMatrix™ (Biosensors Interventional Technologies Pte Ltd.,
Singapore) or Zotarolimus eluting Endeavor Resolute™ (Medtronic, Santa
Rosa, California).
2.2 | Endpoints and definitions
The primary endpoint of the study was the adjusted hazard ratio
(HR) for major adverse cardiac events (MACE: the primary composite
endpoint of all-cause death, target vessel myocardial infarction or tar-
get lesion revascularization). Clinical follow-up data were collected by
hospital visit, chart review, or telephone contact.
Secondary safety endpoints were death from any cause, target
vessel myocardial infarction (MI) defined as any MI to the left coro-
nary tree; target vessel revascularization (TVR) defined as any repeat
intervention of any segment of the left coronary artery system;
including bypass grafting, finally target lesion revascularization (TLR)
defined as revascularisation of the ULMCA and finally stent thrombo-
sis defined as definite stent thrombosis according to the ARC
criteria.18
2.3 | Statistical analysis
Statistical analyses were performed using SPSS (version 24.0, SPSS
Inc., Chicago Ill). Baseline and categorical variables are reported as
either counts or percentages and compared using the Chi Square test.
Baseline, continuous variables are reported as mean ± SD and were
compared using an independent t-test or Wilcoxon-Mann–Whitney
test. For the survival analysis a cut-off of 80% noncensored patients
was taken in order to demonstrate a valid long-term follow-up analy-
sis. Missing data were handled using the multiple imputations method.
Only impaired left ventricular ejection fraction (LVEF) (<35%) had
missing values (34.9%). Values were imputed using the patients' clini-
cal data. Results from five imputed data sets were pooled to obtain
risk estimates. The survival analysis was performed with the Kaplan–
Meier method and tested for significant differences with the Log-
Rank test. Hazard ratios (HR) with pertinent 95% confidence intervals
were calculated using Cox proportional hazards model. Finally, a mul-
tivariate cox-regression analysis was performed in order to assess the
adjusted HR with the corresponding 95% confidence intervals (CI).
The multivariate model consisted of all variables that differed signifi-
cantly between the two generations DES type with the exclusion
DAPT prescription since this was based on clinical guidelines and mid
ULMCA lesions, which was exchanged for ostial ULMCA lesions for
practical reasons. In addition, diabetes, prior MI, prior CABG, ACS as a
clinical presentation and main branch stenting only were included in
the cox regression model.
3 | RESULTS
The present analysis comprises 656 consecutive all-comer patients
who underwent a PCI for ULMCA stenosis at our institution. While
235 patients were treated with 1st-gen DES, a total of 421 patients
were treated with 2nd-gen DES. Within the 1st-gen DES cohort, 91%
received a Paclitaxel-eluting stent. In the 2nd-gen DES cohort, 96%
received an Everolimus-eluting stent. Baseline characteristics are
depicted in Table 1. In brief, the population consisted of 73% males
and 18% presented with an ST-segment elevation myocardial infarct,
7% presented in cardiogenic shock and 14.8% had a LVEF <35%.
Mean age was lower in the 1st-gen DES cohort as compared to the
2nd-gen DES cohort (66.5 ± 11.7 vs. 68.4 ± 11.5, p = .04, respectively)
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and a prior MI and coronary artery bypass grafting (CABG) were more
frequent in the 1st-gen DES cohort. Concomitant RCA disease was
more frequent in the 2nd-gen DES cohort (Table 2). Finally, significant
differences were found in procedural characteristics between both
cohorts, mainly driven by a more frequent use of new generation
P2Y12 inhibitors, radial artery access and intravascular imaging, along
with a lower number of stents, less frequent dual anti-platelet therapy
prescription and higher percentage of complete revascularization in
the 2nd-gen DES cohort (Table 3).
3.1 | Clinical follow-up
Median follow-up time was 1,361 days (range from 0 to 5,031). The
overall cumulative incidence of MACE at 5 years was 37.9%. At
5 years, the cumulative incidence of MACE did not differ between
1st- and 2nd-gen DES (36.8 vs. 38.6%, respectively, Log Rank p = .79,
adjusted HR = 1.23 [95% CI, 0.94–1.74]) (Figure 1). No difference was
observed in all-cause mortality between the 1st-gen DES and 2nd-gen
DES cohorts (29.5 vs. 29%, respectively, p = .88, adjusted HR = 1.19
[95% CI, 0.84–1.68]). Also, cumulative incidences of TV MI (5.0
vs. 8.4%, respectively, p = .17, adjusted HR = 1.75 [95% CI,
0.78–3.96]), TVR (17.5 vs. 20.9% respectively, p = .87, adjusted
HR = 1.21 [95% CI, 0.77–1.91]), TLR (8.1 vs. 9.8%, respectively,
p = .94, adjusted HR = 1.16 [95% CI, 0.59–2.29]) and definite stent
thrombosis (2.0 vs. 1.7% respectively, p = .82, adjusted HR = 0.29
[95% CI, 0.028–2.99]) did not differ significantly.
In the cox multivariate regression analysis, Age (adjusted HR 1.02;
95% CI 1.01–1.03), diabetes (adjusted HR 1.54; 95% CI 1.14–2.08);
acute coronary syndrome (ACS) at presentation (adjusted HR 1.45;
95% CI 1.07–1.96); a two-vessel bifurcation stenting technique
(adjusted HR 1.83; 95% CI 1.24–2.71) were associated with an
increased risk for MACE at 5 years, while complete revascularization
(adjusted HR 0.65; 95% CI 0.47–0.90) was associated with a
decreased risk for 5-year MACE (Table S1).
The cause of death was cardiovascular in 39% of cases, while 29%
was noncardiovascular. In 32%, no details on the cause of death could
be retrieved.
4 | DISCUSSION
In the present study comparing the clinical outcome of patients
treated with 1st- and 2nd-gen DES for ULMCA disease, no difference
between the two generations of DES was found up to 5 years. The
present study provides the longest follow-up to date of patients
treated with both generations DES for ULMCA disease. However,





(n = 421) p-value
Age (years) 66.5 ± 11.7 68.4 ± 11.5 .038
Male gender 174 (74%) 304 (72%) .613
Hypertension 131 (56%) 262 (62%) .104
Hypercholesterolemia 142 (60%) 273 (65%) .260
Diabetes 48 (21%) 101 (24%) .296
Smoking history 83 (35%) 125 (30%) .137
Peripheral arterial disease 35 (15%) 83 (20%) .123
Prior myocardial infarction 93 (40%) 121 (29%) .005
Prior PCI 61 (26%) 122 (29%) .408
Prior PCI left main 2 (1%) 5 (1%) .687
Prior CABG 29 (12%) 32 (8%) .045
Prior stroke 20 (9%) 48 (11%) .244
BMI (kg/m2) 26.6 ± 3.9 27.2 ± 4.9 .098
Hb level (mmol/L) 8.3 ± 1.2 8.3 ± 1.2 .706
Creatinine level (μmol/L) 99.0 ± 71.9 97.8 ± 52.0 .811
Indication for PCI
Stable angina 101 (43%) 176 (42%) .770
Non-ST-segment elevation ACS 94 (40%) 164 (39%) .793
ST segment elevation ACS 40 (17%) 81 (19%) .482
Patient in shock 11 (5%) 36 (9%) .065
Left ventricular ejection fraction <35%a 27 (21%) 36 (12%) .026
Note: Data are n (%) or mean ± SD.
Abbreviations: ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass
grafting; DES, drug-eluting stents;
a43.4% missing in the first-generation DES cohort, 29.9% missing in the second-generation
DES (p = .001).
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MACE rates at 5 years were as high as 37.9%, illustrating the high-risk
nature of the present real-world population.
Although CABG has long been considered the treatment of first
choice for patients presenting with left main disease, PCI is currently
accepted as an alternative to CABG for patients with left main
disease.3,4,19–21 Unfortunately, only 34% of the PCI patients in the
dedicated randomized PCI versus CABG trials were treated with 2nd
generation DES.4 This is an important limitation since newer genera-
tion DES proved successful in reducing issues of delayed healing, late
and very late stent thrombotic events, and late restenosis.22–27 The
latter resulted in new dedicated randomized trials such as the NOBLE,
EXCEL, and SYNTAX, investigating the difference in outcome of PCI
versus CABG in patients with left main coronary artery disease specif-
ically.1,2,10 Besides their partly conflicting results, the one thing these
three trials had in common was that they still included selected
patients. None of the trials included patients with complex multivessel
disease, presentation with acute myocardial infarction or shock and or
frailty. These figures call for registries assessing the outcome of
patients treated in real world clinical practice. In the present study,
53% of the population either presented with a STEMI, cardiogenic
shock or had 3-vessel disease.
Previous research byMoynagh et al. demonstrated that in a propen-
sity matched cohort, Everolimus-eluting stents (2nd-gen DES) were safer
and more effective as compared to Paclitaxel-eluting stents (1st-gen
DES) in 344 patients, with a reduction of TLF up to 53% at 2 years
(cumulative incidence of 7.6 vs. 16.3%, respectively) a difference mainly
driven by a discordance in stent thrombosis and target vessel MI, a
superiority which was also seen in the ERACI IV registry (216
patients).28,29 Although we were not able to show a difference between
1st and 2nd gen DES used for treating ULMCA disease up to 5 years in a
significantly larger series of patients (n = 656), our results extend and
concur with the findings of a recent combined analysis of the ISAR-
LEFT MAIN and ISAR-LEFT MAIN two trial showing comparable find-
ings at 3 years in 1,257 patients.15 Additionally, also in the 24 months
follow-up FINE registry (183 patients) and 18 months follow-up
PRECOMBAT-2 study (661 patients) no differences were found
between both generations of DES.30,31 Additionally, we found MACE
rates that exceeded those reported in previous studies with more selec-
tive inclusion criteria. In the present study, 5-year MACE rates accrued
to 39.5 and 39.7% in the 1st and 2nd-gen DES cohort respectively.
These rates were mainly driven by high all-cause mortality figures of
30 and 29%, respectively. In comparison, in the combined ISAR trials,








(n = 421) p-value
Lesion location
Ostial 70 (30%) 117 (28%) .542
Mid 58 (25%) 143 (34%) .016
Distal 151 (64%) 287 (68%) .343
Bifurcation 163 (69%) 293 (70%) .987
Medina class
1,1,1 77 (47%) 117 (40%)
1,1,0 38 (23%) 116 (40%)
1,0,1 18 (11%) 26 (9%)
0,1,1 6 (4%) 4 (1%)
1,0,0 7 (4%) 11 (1%)
0,1,0 11 (7%) 16 (6%)
0,0,1 6 (4%) 3 (1%)
Concomitant LAD disease 182 (78%) 344 (82%) .225
Concomitant RCX disease 153 (65%) 265 (63%) .581
Concomitant RCA disease 107 (46%) 230 (55%) .029
Chronic occlusion RCA 20 (9%) 59 (14%) .038
RCA dominant 227 (97%) 382 (91%) .005
In-stent restenosis 8 (3%) 8 (2%) .231
Note: Data are n (%).
Abbreviations: DES, drug-eluting stents; LAD, left anterior descending
artery; LCX, left circumflex artery; RCA, right coronary artery.




DES (n = 235)
Second
generation
DES (n = 421) p-value
Radial access 3 (1%) 97 (23%) <.001
Intravascular imaging 84 (36%) 192 (46%) .014
IVUS 84 (36%) 184 (44%) .047
OCT 0 (0%) 10 (2%) .017
Predilatation 152 (65%) 251 (60%) .202
Rotablation 2 (1%) 9 (2%) .218
Intra-aortic balloon pump 31 (13%) 56 (13%) .968
Glycoprotein IIb/IIIa inhibitors 38 (16%) 41 (10%) .015
Stent diameter ULMCA (mm) 3.5 (3.0–4.0) 3.5 (3.5–4.0) .136
Stent length ULMCA (mm) 20 (12–24) 16 (12–20) <.001
Total stent length (mm) 52 (31–88) 39 (20–67) <.001
Number of stents 3 (2–5) 2 (1–4) <.001
Only main branch stenting 167 (71%) 323 (77%) .110
Post dilatation 171 (73%) 277 (66%) .066
Kissing balloon 95 (40%) 129 (31%) .011
Max balloon diameter (mm) 4.0 (3.5–4.5) 4.0 (3.5–4.0) .343
Complete revascularization 136 (58%) 294 (70%) .002
Angiographic success 228 (97%) 418 (99%) .052
Use of Prasugrel or Ticagrelor 3 (1%) 78 (19%) <.001
Anti-platelet therapy
prescription durationa
12 (12–12) 12 (12–12) <.001
Data are n (%), mean ± SD or median (IQR).
Abbreviations: IVUS, intravascular ultrasound, OCT, optical coherence
tomography, ULMCA, unprotected left main coronary artery, DAPT, dual
anti-platelet therapy.
aMean values for anti-platelet therapy duration are 8.6 ± 3.2 and 12.0
± 0.9 for the first and second generation DES, respectively.
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the cumulative incidence of major adverse cardiac and cerebrovascular
events (MACCE) was 28% after 3 years, while all-cause mortality was
observed in only 13%. However, also the ISAR trials had strict exclusion
criteria, such as presence of STEMI, previous CABG, malignancies, car-
diogenic shock or a life expectancy <12 months. In addition, the high
event rates in the present study cohort, irrespective of the type of DES
used, indicates the extreme high risk nature of the present ULCA
patient population. It is therefore likely that the small number of events
driven by differences in stent type was mitigated by the events linked
to the overall patient risk and frailty, both cardiac and noncardiac of
many of these patients. The latter calls for better pharmacotherapy,
tools and techniques to optimize the outcome of these high-risk
patients.
In a dedicated cox multivariable regression analysis, we were able
to demonstrate that Age, diabetes, ACS at presentation, a two-stent
technique and incomplete revascularization were associated with an
increased risk for MACE at 5 years. The latter is in line with prior
research on 2 year follow-up, indicating worse outcome in patients
presenting with ACS.32 Furthermore, also diabetes has previously
been shown to negatively influence MACCE rates at 1–3 years
follow-up after treatment of ULMCA stenosis.15,33,34 Regarding the
use of a 1- versus 2-stent strategy to treat LMCA bifurcation lesions,
most previous trials concluded noninferiority between strategies.34–38
Nevertheless, the recent DK crush V trial suggested a lower rate of
TLF at 1 year in the two-stent strategy group as compared to a one
stent provisional stenting technique.39 However, the study protocol
advocated a truly complex two-vessel stenting technique, which, in
common practice might not always be a realistic solution.
Finally, complete percutaneous revascularization has been shown
to significantly reduce cardiovascular endpoint in patients with multi-
vessel disease in a large meta-analysis of trials mainly focusing on
patients with stable or unstable coronary artery disease.40 Conversely,
in the recently published CULPRIT Shock trial multivessel PCI did not
reduce the primary composite endpoint of death or severe renal fail-
ure within 30 days after randomization as compared to culprit artery
only revascularization.41 Instead, the 30-day risk of the primary end-
point was lower among those who initially underwent PCI of the cul-
prit lesion only than among those who underwent immediate
multivessel PCI. Of note, only 8% of the patients in this trial presented
with left main disease and longer-term follow-up of these patients is
not yet available. To date, no dedicated randomized trial has assessed
the superiority of complete revascularization as compared to culprit
only PCI in patients with ULMCA stenosis. In order to indefinitely
adjudicate, the potential influence of multiple stenting techniques,
large randomized controlled trials are warranted, for example the EBC
MAIN (NCT02497014).
5 | LIMITATIONS
Several limitations need to be mentioned. First, all patients from the
current study were included in a large tertiary referring hospital,
inducing possible inclusion bias and external validity is therefore not
verified. Second, the allocation to treatment with either a 1st- or 2nd-
gen DES was determined by the time at which a patient was included.
The latter resulted in two consecutive real-world patient cohorts
included over a time period of 12 years in which routine clinical prac-
tice changed. As a result, several significant differences were found
between both cohorts in baseline and procedural characteristics. It is
likely, that despite extensive regression models we were not able to
fully account for the differences between both cohorts. In addition,
given the retrospective nature of the study cohort going back to
patients treated in 2002 we were not able to obtain the cause of
F IGURE 1 Outcome Kaplan-Meijer
curves for both first- and second-
generation drug eluting stents, including
unadjusted hazard ratios and log rank
p values at 5 years follow-up. (a) All-
cause mortality event free survival at
5 years follow-up. (b) All-cause mortality
event free survival at 5 years follow-up.
(c) Target vessel myocardial infarction
event free survival at 5 years follow-up.
(d) Target lesion revascularization event
free survival at 5 years follow-up
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death in a significant proportion of patients. Cerebrovascular events
were not assessed in the current study and therefore, a completely
valid comparison to for example the combined ISAR trial and SYNTAX
trial might not be possible. Finally, clinical events were adjudicated by
local interventional cardiologists (JD, RvB) with access to all patient
data, without external validation.
6 | CONCLUSION
In this large cohort of consecutive patients treated for ULMCA steno-
sis, no significant differences were found in the safety and efficacy of
1st-versus 2nd-gen DES at 5 years follow-up. Long-term adverse event
rates following ULMCA stenting remain high.
6.1 | What is known about the topic?
Treatment of unprotected left main coronary artery stenosis (ULMCA)
with drug eluting stent (DES) is now recognized as an alternative to
coronary artery bypass grafting in selected patients. In order to
decrease the incidence of adverse events like late and very late stent
thrombosis with the 1st generation DES, 2nd generation DES were
developed with better deliverable alloys, less thrombogenic surface
and thinner struts. The success of these device iterations was proven
by better outcomes in a general PCI population.
6.2 | What does this study add?
In the present study, comparing the clinical outcome of patients
treated with 1st- and 2nd-gen DES for ULMCA disease, no difference
between the two generations of DES was found up to 5 years. The
present study provides the longest follow-up to date of patients
treated with both generations DES for ULMCA disease. However,
MACE rates at 5 years were as high as 37.9%, illustrating the high-risk
nature of the present real-world population.
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